[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"moderate-aortic-valve-stenosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:moderate-aortic-valve-stenosis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100593081","phase-2-ataciguat-for-slowing-the-progression-of-moderate-calcific-aortic-valve-stenosis-a-randomized-placebo-controlled-study-100593081",false,"NCT07001800","Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study","A Phase 2b\u002F3, Randomized, Double-Blinded, Placebo Controlled Study ChecKing the Efficacy and Safety of ATAciguat to Slow the Progression of VaLvular DYsfunction in Participants With Moderate Calcific Aortic Valve STenosis","KATALYST-AV","Key Inclusion Criteria:\n\n1. Adult male or female at least 50 years of age\n2. Has moderate CAVS as defined by:\n\n   1. An AVA of ≥1.0 cm2 to ≤1.50 cm2\n   2. An AVC score between \\>300 to 1200 Agatston units (AU) for women and between \\>300 to 2000 AU for men\n3. Has a left ventricular ejection fraction (EF) of ≥45% at the time of Screening as determined by the echocardiography Imaging Core Laboratory\n4. For participants in CPET sub-study in Part A and all participants in Part B: If on beta blockade, the dose must be stable for at least 90 days prior to the Screening Visit with no anticipated changes during the study\n\nKey Exclusion Criteria:\n\n1. For participants in the CPET sub-study in Part A and all participants in Part B: Has any medical or physical condition that, in the Investigator's opinion, could lead to an inability to complete Protocol-required CPET procedures (eg, pulmonary disease, joint, leg, hip, back conditions that limit physical activity, or other absolute contraindications for CPET)\n2. Anticipated or planned prior aortic valve replacement, repair, surgery, or intervention in the next 6 months\n3. Has moderate, moderate-to-severe, or severe (Grade 2 or higher) mitral stenosis, mitral regurgitation, and\u002For aortic regurgitation\n4. Has suspected or known congenital aortic valve disease including bicuspid aortic valve\n5. New York Heart Association (NYHA) Class IV heart failure symptoms and\u002For requires continuous inotropes\n6. Has history of hypertrophic, genetic\u002Ffamilial cardiomyopathy or cardiomyopathy related to amyloid or sarcoid\n7. Has untreated obstructive coronary artery disease or anticipating coronary stenting surgery\n8. Abnormal electrocardiogram (ECG) results or long-standing persistent or permanent atrial fibrillation","ALL","50 Years",{"count":20,"type":21},1276,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","The purpose of this study is to evaluate if ataciguat slows the progression of moderate calcific aortic valve stenosis in adults.",[28],"Moderate Aortic Valve Stenosis",[30,31,32,33,34,35,36,37,38],"Ataciguat","sGC activator","sGC stimulator","Aortic valve stenosis","Moderate aortic valve stenosis","Calcific aortic valve stenosis","CAVS","Moderate Calcific Aortic Valve Stenosis","Aortic Stenosis (AS)","RECRUITING","2026-05-04",{"date":42,"type":43},"2026-05-06","ACTUAL",{"date":45,"type":43},"2025-06-27",{"date":47,"type":21},"2030-09-30",{"name":49,"class":50},"Kardigan, Inc.","INDUSTRY",70,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":63,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100529003","future-optimal-research-and-care-evaluation---aortic-stenosis-100529003","NCT06168123","Future Optimal Research and Care Evaluation - Aortic Stenosis","FORCE-AoS","Inclusion Criteria:\n\n* Older than 18 years of age\n* Severe or moderate aortic stenosis\n\nNo exclusion criteria are applicable to this registry","18 Years","110 Years",{"count":62,"type":21},800,"4 Years","OBSERVATIONAL","In the past decade the treatment of aortic valve stenosis has rapidly changed. At first, transcatheter aortic valve implantation (TAVI) was a last resort option for inoperable patients. Nowadays, it more and more becomes an alternative to surgical aortic valve replacement (SAVR) - also in younger and lower risk patients. This poses important questions to clinical practise regarding the optimal life-time management of each individual patient. Which involves (durability of) treatment modality (surgical vs. transcatheter vs. conservative treatment) as well as the duration and type of the required antithrombotic treatment.\n\nObjective: to evaluate the effect of treatment modality (surgical vs. transcatheter vs. conservative treatment) and its complications on quality of life and survival in AoS patients.",[67,28],"Severe Aortic Valve Stenosis","2024-11-28",{"date":70,"type":43},"2024-12-03",{"date":72,"type":43},"2023-11-27",{"date":74,"type":21},"2027-08-01",{"name":76,"class":77},"St. Antonius Hospital","OTHER",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":78},"100561886","prospective-observational-cohort-study-of-moderate-aortic-valve-disease-100561886","NCT06595992","Prospective Observational Cohort Study of Moderate Aortic Valve Disease","EVOLUTION: Prospective Observational Cohort Study of Moderate Aortic Valve Disease","Inclusion Criteria:\n\n* At least 18 years old\n* Be willing and able to provide informed consent to participate in the study\n* Patient has moderate aortic valve diseases with echocardiographically derived criteria\n\nExclusion Criteria:\n\n* Severe aortic valve diseases with echocardiographically derived criteria or planned cardiac surgery or likely need for surgery within 6 months\n* Patients who have undergone elective transfemoral transcatheter aortic valve replacement\n* Life expectancy is less than 12 months due to non-heart disease (such as cancer, chronic liver disease, chronic kidney disease, or chronic end-stage lung disease, etc.)\n* Severe dementia (cannot sign research informed consent, cannot take care of themselves or complete the study visit)\n* Acute pulmonary oedema or cardiogenic shock\n* The investigator believes that the patient is not suitable to participate in the study or complete the follow-up prescribed by the protocol from other medical, social and psychological aspects\n* The patient is currently participating in another randomized study",{"count":87,"type":21},1000,"The objective of this research is to evaluate and predict the progression of moderate aortic stenosis and regurgitation from clinical characterization, biological, echocardiographic, and computed tomography (CT) et. al. Additionally, try to analyze the potential impact of device or drug therapy on the progression of the conditions.",[28,90,91],"Moderate Aortic Valve Regurgitation","Aortic Valve Disease",[93,94,95],"Aortic Valve Disease Progression","Mortality","Heart Failure","2024-09-11",{"date":98,"type":43},"2024-09-19",{"date":100,"type":43},"2024-09-01",{"date":102,"type":21},"2034-01",{"name":104,"class":77},"Second Affiliated Hospital, School of Medicine, Zhejiang University"]